Stocks / NASDAQ / Maze Therapeutics Inc.

Maze Therapeutics Inc.

Industry: Health Care – Biotechnology: Biological Products (No Diagnostic Substances)

Stock Symbol: MAZE – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Maze Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in the following report that they exploit animals for product testing.

“These data demonstrated that MZE829 was substantially more potent than our synthesis of inaxaplin in a translationally relevant animal model, and suggest that meaningful efficacy in the clinic may be achievable at lower levels of free drug. Therefore, we believe MZE829 may be more suitable for clinical exploration in a broader range of patients, with lower risk of off-target safety effects.” (Page 119) Read the full document

Company Description

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Company Website: https://www.mazetx.com

Contact: abachrodt@mazetx.com